| Market Cap | 506.09M | P/E | - | EPS this Y | 5.00% | Ern Qtrly Grth | - |
| Income | -78.5M | Forward P/E | -8.59 | EPS next Y | 70.40% | 50D Avg Chg | -5.00% |
| Sales | 17.49M | PEG | 0.09 | EPS past 5Y | - | 200D Avg Chg | 15.00% |
| Dividend | N/A | Price/Book | 6.20 | EPS next 5Y | -126.60% | 52W High Chg | -21.00% |
| Recommedations | 1.90 | Quick Ratio | 4.73 | Shares Outstanding | 76.03M | 52W Low Chg | 93.00% |
| Insider Own | 12.40% | ROA | -37.06% | Shares Float | 49.83M | Beta | 0.19 |
| Inst Own | 51.32% | ROE | -114.01% | Shares Shorted/Prior | 8.07M/7.26M | Price | 7.82 |
| Gross Margin | 83.49% | Profit Margin | - | Avg. Volume | 653,758 | Target Price | 23.86 |
| Oper. Margin | -583.45% | Earnings Date | May 2 | Volume | 339,815 | Change | 0.26% |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
| Needham | Buy | Apr 10, 24 |
| Needham | Buy | Apr 1, 24 |
| HC Wainwright & Co. | Buy | Mar 14, 24 |
| Needham | Buy | Mar 13, 24 |
| Needham | Buy | Feb 21, 24 |
| Needham | Buy | Jan 5, 24 |
| Ladenburg Thalmann | Buy | Dec 21, 23 |
| B of A Securities | Buy | Dec 21, 23 |
| Wedbush | Underperform | Dec 21, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Adair Jason | Chief Business Offic.. Chief Business Officer | Dec 18 | Sell | 7.7 | 77 | 593 | 54,932 | 12/20/23 |
| JEFFS ROGER | Chief Executive Offi.. Chief Executive Officer | Dec 14 | Buy | 7.16 | 139,665 | 1,000,001 | 640,805 | 12/18/23 |
| Manning Paul B | Director Director | Dec 14 | Buy | 7.16 | 279,330 | 2,000,003 | 279,330 | 12/18/23 |
| Caligan Partners LP | - - | Dec 14 | Buy | 7.16 | 1,117,318 | 7,999,997 | 11,280,945 | 12/14/23 |
| Lippe Robert A | Chief Operations Off.. Chief Operations Officer | Nov 30 | Sell | 7.28 | 497 | 3,618 | 193,788 | 12/05/23 |
| Moomaw Scott | Chief Commercial Off.. Chief Commercial Officer | Nov 30 | Sell | 7.28 | 542 | 3,946 | 106,737 | 12/05/23 |
| Adair Jason | Chief Business Offic.. Chief Business Officer | Nov 30 | Sell | 7.28 | 452 | 3,291 | 54,478 | 12/05/23 |
| Adair Jason | Chief Business Offic.. Chief Business Officer | Sep 19 | Sell | 6.51 | 75 | 488 | 53,637 | 09/20/23 |
| Lippe Robert A | Chief Operations Off.. Chief Operations Officer | Aug 31 | Sell | 6.88 | 505 | 3,474 | 192,567 | 09/05/23 |
| Moomaw Scott | Chief Commercial Off.. Chief Commercial Officer | Aug 31 | Sell | 6.88 | 537 | 3,695 | 105,404 | 09/05/23 |
| Adair Jason | Chief Business Offic.. Chief Business Officer | Aug 31 | Sell | 6.88 | 445 | 3,062 | 53,452 | 09/05/23 |
| Moomaw Scott | Chief Commercial Off.. Chief Commercial Officer | May 31 | Sell | 8.08 | 651 | 5,260 | 102,268 | 06/02/23 |
| Lippe Robert A | Chief Operations Off.. Chief Operations Officer | Feb 28 | Sell | 7.56 | 2,033 | 15,369 | 188,524 | 03/02/23 |
| Moomaw Scott | Chief Commercial Off.. Chief Commercial Officer | Feb 28 | Sell | 7.56 | 2,171 | 16,413 | 100,984 | 03/02/23 |
| Kaseta Michael | Chief Financial Offi.. Chief Financial Officer | Sep 13 | Buy | 5.99 | 8,000 | 47,920 | 37,877 | 09/14/22 |
| JEFFS ROGER | Chief Executive Offi.. Chief Executive Officer | Sep 06 | Buy | 5.568 | 43,820 | 243,990 | 159,827 | 09/07/22 |
| Caligan Partners LP | - - | Sep 06 | Buy | 5.62 | 250,000 | 1,405,000 | 10,643,627 | 09/07/22 |
| Moomaw Scott | SVP, Commercial SVP, Commercial | Aug 31 | Buy | 4.9045 | 2,160 | 10,594 | 9,810 | 09/01/22 |
| Lippe Robert A | Chief Operations Off.. Chief Operations Officer | Aug 31 | Buy | 4.9045 | 1,918 | 9,407 | 98,026 | 09/01/22 |
| Kaseta Michael | Chief Financial Offi.. Chief Financial Officer | Aug 31 | Buy | 4.9045 | 1,927 | 9,451 | 29,877 | 09/01/22 |
| JEFFS ROGER | Chief Executive Offi.. Chief Executive Officer | Aug 31 | Buy | 4.9045 | 993 | 4,870 | 116,007 | 09/01/22 |
| Kaseta Michael | Chief Financial Offi.. Chief Financial Officer | May 31 | Buy | 4.01 | 18,700 | 74,987 | 27,950 | 06/01/22 |
| Caligan Partners LP | - - | May 25 | Buy | 3.40 | 79,400 | 269,960 | 10,393,627 | 05/26/22 |
| Lippe Robert A | Chief Operations Off.. Chief Operations Officer | May 24 | Buy | 3.3751 | 29,628 | 99,997 | 90,692 | 05/25/22 |
| JEFFS ROGER | Chief Executive Offi.. Chief Executive Officer | May 24 | Buy | 3.529 | 28,000 | 98,812 | 46,595 | 05/25/22 |
| Caligan Partners LP | - - | May 17 | Buy | 5.9 | 221,104 | 1,304,514 | 10,314,227 | 05/19/22 |
| Caligan Partners LP | - - | Apr 18 | Buy | 5.10 | 1,764,705 | 8,999,996 | 10,093,123 | 04/18/22 |